Literature DB >> 26525551

Paradox of using intensive lowering of blood glucose in diabetics and strategies to overcome it and decrease cardiovascular risks.

Xian-pei Heng1, Liu-qing Yang2, Min-ling Chen2, Liang Li2, Su-ping Huang3, Ying Lei4.   

Abstract

Hyperglycemia significantly increases the risk of cardiovascular disease (CVD) in diabetics. However, it has been shown by a series of large scale international studies that intensive lowering of blood glucose levels not only has very limited benefits against cardiovascular problems in patients, but may even be harmful to patients at a high risk for CVD and/or poor long-term control of blood glucose levels. Therefore, Western medicine is faced with a paradox. One way to solve this may be administration of Chinese herbal medicines that not only regulate blood glucose, blood fat levels and blood pressure, but also act on multiple targets. These medicines can eliminate cytotoxicity of high glucose through anti-inflammatory and anti-oxidant methods, regulation of cytokines and multiple signaling molecules, and maintenance of cell vitality and the cell cycle, etc. This allows hyperglycemic conditions to exist in a healthy manner, which is called "harmless hyperglycemia" Furthermore, these cardiovascular benefits go beyond lowering blood glucose levels. The mechanisms of action not only avoid cardiovascular injury caused by intensive lowering of blood glucose levels, but also decrease the cardiovascular dangers posed by hyperglycemia.

Entities:  

Keywords:  Chinese herbal medicine; cardiovascular risk; diabetes; glucose toxicity; harmless hyperglycemia

Mesh:

Substances:

Year:  2015        PMID: 26525551     DOI: 10.1007/s11655-015-0780-5

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  40 in total

1.  A novel AMPK activator from Chinese herb medicine and ischemia phosphorylate the cardiac transcription factor FOXO3.

Authors:  Jingying Wang; Heng Ma; Xiaoyu Zhang; Leilei He; Jianming Wu; Xiaoping Gao; Jun Ren; Ji Li
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2009-03-25

2.  Very tight glucose control: May be high risk, low benefit.

Authors:  John S Yudkin
Journal:  BMJ       Date:  2008-03-29

3.  Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Authors:  Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

4.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

5.  Insulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 diabetes mellitus.

Authors:  Larissa Avilés-Santa; Karin Salinas; Beverley Adams-Huet; Philip Raskin
Journal:  J Investig Med       Date:  2006-01       Impact factor: 2.895

6.  Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10-year prospective cohort study.

Authors:  Henna Cederberg; Tuula Saukkonen; Mauri Laakso; Jari Jokelainen; Pirjo Härkönen; Markku Timonen; Sirkka Keinänen-Kiukaanniemi; Ulla Rajala
Journal:  Diabetes Care       Date:  2010-06-23       Impact factor: 17.152

7.  Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Authors:  Connie Kingry; Arnaud Bastien; Gillian Booth; Therese S Geraci; Brenda R Kirpach; Laura C Lovato; Karen L Margolis; Yves Rosenberg; JoAnne M Sperl-Hillen; Laura Vargo; Jeff D Williamson; Jeffrey L Probstfield
Journal:  Am J Cardiol       Date:  2007-04-12       Impact factor: 2.778

8.  Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Authors:  Denise E Bonds; Ella Mae Kurashige; Richard Bergenstal; David Brillon; Michael Domanski; James V Felicetta; Vivian A Fonseca; Kathleen Hall; Irene Hramiak; Michael E Miller; Kwame Osei; Denise G Simons-Morton
Journal:  Am J Cardiol       Date:  2007-04-17       Impact factor: 2.778

9.  Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice.

Authors:  Aimin Xu; Hongbing Wang; Ruby L C Hoo; Gary Sweeney; Paul M Vanhoutte; Yu Wang; Donghai Wu; Wenjing Chu; Guowei Qin; Karen S L Lam
Journal:  Endocrinology       Date:  2008-10-16       Impact factor: 4.736

10.  Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Authors:  Jorge Calles-Escandón; Laura C Lovato; Denise G Simons-Morton; David M Kendall; Rodica Pop-Busui; Robert M Cohen; Denise E Bonds; Vivian A Fonseca; Faramarz Ismail-Beigi; Mary Ann Banerji; Alan Failor; Bruce Hamilton
Journal:  Diabetes Care       Date:  2010-01-26       Impact factor: 17.152

View more
  2 in total

Review 1.  Therapy to Obese Type 2 Diabetes Mellitus: How Far Will We Go Down the Wrong Road?

Authors:  Xian-Pei Heng; Xiu-Jun Li; Liang Li; Liu-Qing Yang; Zi-Ta Wang; Su-Ping Huang
Journal:  Chin J Integr Med       Date:  2018-10-17       Impact factor: 1.978

2.  Azoramide improves mitochondrial dysfunction in palmitate-induced insulin resistant H9c2 cells.

Authors:  Esma Nur Okatan; Yusuf Olgar; Erkan Tuncay; Belma Turan
Journal:  Mol Cell Biochem       Date:  2019-07-20       Impact factor: 3.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.